1 Min Read
Dec 5 (Reuters) - Fortress Biotech Inc:
* FORTRESS BIOTECH FORMS SUBSIDIARY TAMID BIO TO DEVELOP NOVEL AAV GENE THERAPIES IN ORPHAN DISEASES WITH UNMET MEDICAL NEEDS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.